Bristol-Myers kidney cancer drug meets main goal of late-stage trial
September 07, 2017 at 07:22 AM EDT
Sept 7 (Reuters) - Bristol-Myers Squibb Co said on Thursday its combination drug to treat a type of kidney cancer met one of the main goals of overall survival in a late-stage study.
